MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from initial
public offering
$327,750K
Proceeds from exercise of
warrants and options
$247K
Net cash provided by
financing activities
$302,562K
Canceled cashflow
$25,435K
Net increase in
cash, cash...
$227,467K
Canceled cashflow
$75,095K
Payment of issuance
costs for initial...
$25,435K
Proceeds from the sale of
marketable securities
$2,501K
Maturities of marketable
securities
$2,500K
Stock-based compensation
expense
$4,191K
Depreciation and
amortization
$321K
Amortization (accretion) of
premiums (discounts) on...
-$261K
Noncash lease expense
$147K
Loss on write off of
property and equipment
$8K
Net cash (used in)
provided by investing...
-$39,887K
Net cash used in
operating activities
-$35,208K
Canceled cashflow
$5,001K
Canceled cashflow
$4,928K
Non-operating income
$5,200K
Purchase of marketable
securities
$44,836K
Net loss
-$25,205K
Prepaid expenses and
other current assets
$12,339K
Purchases of property and
equipment
$52K
Canceled cashflow
$5,200K
(gain) loss on change in
fair value of...
$1,161K
Accounts payable and
accrued expenses
-$910K
Accrued interest on
marketable securities
-$268K
Operating lease liability
-$134K
Realized gain on sale of
marketable securities, net
$119K
Total operating loss
$30,404K
Income tax provision
$1K
Total research and
development expenses
$16,744K
General and
administrative expenses
$13,660K
Back
Back
Cash Flow
source: myfinsight.com
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)